CORAL SPRINGS, Fla. and NETANYA, Israel, Aug. 21, 2025 /PRNewswire/ -- Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a strategic investment from BrainsWay Ltd. (NASDAQ & TASE: BWAY), a publicly-traded global...
Related Questions
How will BrainsWay’s strategic investment in Neurolief affect BWAY’s stock valuation and liquidity?
What are the expected revenue timelines and market penetration rates for the Proliv™Rx system targeting Major Depressive Disorder?
How does Neurolief’s non‑invasive neuromodulation platform compare to existing MDD treatments and competitor neuromodulation technologies in terms of efficacy, regulatory pathway, and pricing?